Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353069 | 0.82 | HTR1A (0.38) | CA1CA2EPHX2TDP1L3MBTL1 | |
| SCHEMBL18775726 | 0.78 | HSD11B1 (0.37) | — | |
| SCHEMBL5503709 | 0.74 | EPHX2 (0.36) | EPHX2TDP1L3MBTL1DPP4HSD17B10 | |
| SCHEMBL5506446 | 0.71 | KDM4E (0.46) | CA1LMNASMN1; SMN2 | |
| SCHEMBL5504913 | 0.71 | ADRB3 (0.38) | EPHX2DPP4SMN1; SMN2 | |
| SCHEMBL18747650 | 0.70 | LMNA (0.46) | CA1CA2EPHX2TDP1L3MBTL1 | |
| SCHEMBL5505906 | 0.70 | KDM4E (0.48) | CA1CA2EPHX2LMNASMN1; SMN2 | |
| SCHEMBL5506825 | 0.70 | KDM4E (0.48) | CA1CA2EPHX2LMNASMN1; SMN2 | |
| SCHEMBL13330072 | 0.68 | LMNA (0.47) | CA1CA2EPHX2TDP1L3MBTL1 | |
| SCHEMBL14100188 | 0.68 | LMNA (0.47) | CA1CA2EPHX2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828111-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
| WO-2006059252-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | CA1 291/4885CA2 1329/4885EPHX2 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.